These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 34338119)

  • 1. New benzothieno[2,3-
    Khalil NA; Ahmed EM; Zaher AF; Sobh EA; El-Sebaey SA; El-Zoghbi MS
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1839-1859. PubMed ID: 34338119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
    Hou Q; He C; Lao K; Luo G; You Q; Xiang H
    Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
    Hu Q; Yin L; Jagusch C; Hille UE; Hartmann RW
    J Med Chem; 2010 Jul; 53(13):5049-53. PubMed ID: 20550118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.
    Wang M; Fang Y; Gu S; Chen F; Zhu Z; Sun X; Zhu J
    Eur J Med Chem; 2017 May; 132():157-172. PubMed ID: 28350999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of new steroidal pyridines as potential anti-prostate cancer agents.
    Shi YK; Wang B; Shi XL; Zhao YD; Yu B; Liu HM
    Eur J Med Chem; 2018 Feb; 145():11-22. PubMed ID: 29310026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
    Rafferty SW; Eisner JR; Moore WR; Schotzinger RJ; Hoekstra WJ
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2444-7. PubMed ID: 24775307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
    J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.
    Madadi NR; Penthala NR; Ketkar A; Eoff RL; Trujullo-Alonso V; Guzman ML; Crooks PA
    Anticancer Agents Med Chem; 2018; 18(4):556-564. PubMed ID: 28403783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
    Hu Q; Jagusch C; Hille UE; Haupenthal J; Hartmann RW
    J Med Chem; 2010 Aug; 53(15):5749-58. PubMed ID: 20684610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-substituted piperazinopyridylsteroid derivatives as abiraterone analogues inhibit growth and induce pro-apoptosis in human hormone-independent prostate cancer cell lines.
    Brossard D; Zhang Y; Haider SM; Sgobba M; Khalid M; Legay R; Duterque-Coquillaud M; Galera P; Rault S; Dallemagne P; Moslemi S; El Kihel L
    Chem Biol Drug Des; 2013 Nov; 82(5):620-9. PubMed ID: 23906044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
    Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
    Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational prediction of new CYP17 inhibitors based on pharmacophore modeling, virtual screening and docking approach.
    Haidar S; Hartmann RW
    Pharmazie; 2017 Sep; 72(9):529-536. PubMed ID: 29441980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAF
    Ali EMH; Mersal KI; Ammar UM; Zaraei SO; Abdel-Maksoud MS; El-Gamal MI; Haque MM; Das T; Kim EE; Lee JS; Lee KH; Kim HK; Oh CH
    Eur J Pharm Sci; 2022 Apr; 171():106115. PubMed ID: 34995782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of 2-substituted Furo[3,2-b]pyridines Under Pd/C-Cu Catalysis Assisted by Ultrasound: Their Evaluation as Potential Cytotoxic Agents.
    Laxmi DS; Vardhini SV; Guttikonda VR; Rao MVB; Pal M
    Anticancer Agents Med Chem; 2020; 20(8):932-940. PubMed ID: 32160853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, 17α-hydroxylase-C
    Banday AH; Shameem SA; Banday JA; Ganaie BA
    Anticancer Agents Med Chem; 2018; 18(13):1919-1926. PubMed ID: 29697032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases.
    Pinto-Bazurco Mendieta MA; Hu Q; Engel M; Hartmann RW
    J Med Chem; 2013 Aug; 56(15):6101-7. PubMed ID: 23859149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel benzotriazole N-acylarylhydrazone hybrids: Design, synthesis, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and FAK inhibition.
    Kassab AE; Hassan RA
    Bioorg Chem; 2018 Oct; 80():531-544. PubMed ID: 30014921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.
    Hille UE; Hu Q; Vock C; Negri M; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
    Eur J Med Chem; 2009 Jul; 44(7):2765-75. PubMed ID: 19211174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.
    Hassig CA; Symons KT; Guo X; Nguyen PM; Annable T; Wash PL; Payne JE; Jenkins DA; Bonnefous C; Trotter C; Wang Y; Anzola JV; Milkova EL; Hoffman TZ; Dozier SJ; Wiley BM; Saven A; Malecha JW; Davis RL; Muhammad J; Shiau AK; Noble SA; Rao TS; Smith ND; Hager JH
    Mol Cancer Ther; 2008 May; 7(5):1054-65. PubMed ID: 18483295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP17 inhibitors for prostate cancer treatment--an update.
    Moreira VM; Salvador JA; Vasaitis TS; Njar VC
    Curr Med Chem; 2008; 15(9):868-99. PubMed ID: 18473796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.